NCT02654509已完成2 期
Phase 2 Open-Label Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus
U.S. Army Medical Research and Development Command2 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2008年6月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 138
- 试验地点
- 2
- 主要终点
- Post-Vaccination Adverse Events by System Organ Class and Severity
研究概览
简要总结
This study is being conducted to collect safety and immunogenicity data for the Eastern Equine Encephalitis (EEE) vaccine.
详细描述
This study is being conducted to collect safety and immunogenicity data for the Eastern Equine Encephalitis (EEE) vaccine. To determine the frequency of adverse events in this Eastern Equine Encephalitis (EEE) vaccine study for all intent-to-treat subjects will be evaluated. Also the frequency of clinically confirmed and documented cases of Eastern Equine Encephalitis (EEE) disease among vaccinated subjects compliant with titer schedule after working with Eastern Equine Encephalitis (EEE) virus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be 18 to 65 years old at time of consent.
- •Have EEE virus plaque reduction neutralization 80% titers (PRNT80) < 1:20 for primary series.
- •Have EEE virus PRNT80 < 1:40 for booster series.
- •If female of childbearing potential, must agree to have a urine pregnancy test on the same day before each vaccine. (Exception: documented hysterectomy or ≥ 3 years of menopause.) The results must be negative. Females must agree not to become pregnant for 3 months after receipt of the last study treatment (vaccination).
- •Be considered at risk for exposure to EEE virus and who have submitted a Request for IND Vaccines for the EEE vaccine.
- •Sign and date the approved informed consent document and HIPAA Authorization.
- •Have in their charts:
- •medical history (including concomitant medications) within 60 days of planned first administration of vaccine
- •physical examination and laboratory tests within 1 year
- •previous chest radiograph results and electrocardiogram
- •Be medically cleared for participation by an investigator. (Examinations and/or tests may be repeated at the discretion of the principal investigator [PI].)
- •Be willing to return for all follow-up visits.
- •Agree to report any adverse events (AEs) that may or may not be associated with administration of the vaccine for at least 28 days after administration and agree to report all serious adverse events (for example, resulting in hospitalization) for the duration of the subject's participation in the study. Subjects must agree to report any pregnancy that occurs within 3 months after a vaccination.
- •Agree to defer blood, bone marrow, and organ donation for 1 year after receipt of the vaccine.
排除标准
- •Have completed previous EEE vaccine study as a nonresponder.
- •Have clinically significant abnormal laboratory results (including evidence of hepatitis C, hepatitis B carrier state) or elevated liver function tests (two times the normal range or at the discretion of the PI).
- •Have a personal history of an immunodeficiency or received treatment with an immunosuppressive medication, such as systemically administered glucocorticoids (eg, prednisone) within 1 month before planned administration of the vaccine or with other immunosuppressive therapies within 6 months of planned administration of the vaccine. Other immunosuppressive therapies include all cancer chemotherapeutic agents, drugs to prevent transplant rejection, interferons, monoclonal antibodies, protein kinase inhibitors, methotrexate, TNF (tumor necrosis factor) inhibitors, and any other drug determined to be immunosuppressive by the PI. Current administration of topical, inhalational, or intranasal glucocorticoids is not excluded.
- •Have confirmed HIV infection (antibody positivity).
- •Have positive pregnancy test or be a breastfeeding female.
- •Have any known allergies to components of the vaccine:
- •Neomycin sulfate
- •Formaldehyde
- •Human serum albumin
- •Sodium bisulfite
- •Have administration of another vaccine or investigational product within 28 days of EEE vaccination.
- •Have any unresolved AE resulting from a previous immunization.
- •Have a medical condition that, in the judgment of the PI, would impact subject safety.
结局指标
主要结局
Post-Vaccination Adverse Events by System Organ Class and Severity
时间窗: 30 days
The determined adverse events after vaccination (1 month) as reported by participants by severity and system organ class.
Post-Primary Related Adverse Events by System Organ Class and Severity
时间窗: 11-13 months
The determined adverse events after primary (11-13 months) as reported by participants by severity and system organ class.
Post-Booster Related Adverse Events by System Organ Class and Severity
时间窗: 1-5 weeks
The determined adverse events after primary (1-5 weeks) as reported by participants by severity and system organ class.
次要结局
- % vaccinated subjects with PRNT80 ≥ 1:40 after primary series.(11-13 months)
- % vaccinated subjects with PRNT80 ≥ 1:40 at 11-13 months after first primary dose.(11-13 months)
- % vaccinated subjects with PRNT80 ≥ 1:40 after 6-month booster dose.(6 months)
- % vaccinated subjects with PRNT80 ≥ 1:40 after week 1, 2, 3, or 4 booster doses.(1-4 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) VaccineEastern Equine EncephalitisNCT00584805U.S. Army Medical Research and Development Command138
Unknown
2 期
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83Venezuelan Equine EncephalomyelitisNCT00582088U.S. Army Medical Research and Development Command500
Unknown
2 期
Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis VaccineVenezuelan Equine EncephalomyelitisNCT00582504U.S. Army Medical Research and Development Command500
已完成
2 期
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsInfluenzaNCT05606965ModernaTX, Inc.172
Unknown
2 期
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy AdultsVenezuelan Equine Encephalomyelitis Virus DiseaseNCT03051386U.S. Army Medical Research and Development Command500